The State owned Assets Supervision and Administration Commission of the State Council (SASAC) reported on September 2 that from August 27 to 30, SASAC and the Chinese Academy of Sciences jointly held an advanced seminar on biotechnology industry for central enterprises. Tan Zuojun, deputy director of the State owned Assets Supervision and Administration Commission of the State Council, said that it is necessary to focus on serving the construction of a healthy China, accelerate the development of the central enterprise's biomedical industry, adhere to innovation driven development, long-term development, and differentiated development, through in-depth learning, thought collision, and brainstorming, more clearly study the development trend of the biomedical industry, more accurately grasp the key direction and implementation path of the development of central enterprises, more actively promote collaborative innovation with the Chinese Academy of Sciences, accelerate the building of a national team in the field of biomedicine, and promote the high-quality development of China's biomedical industry. In March of this year, the Party Committee of the State owned Assets Supervision and Administration Commission of the State Council published a signed article in the weekly magazine "Democracy and Legal System", stating that for areas with relatively weak industrial foundations such as biomedicine, state-owned enterprises are encouraged to use various methods such as mergers and acquisitions, equity investments, and industrial funds to accelerate the formation of industrial influence. Recently, China National Pharmaceutical Group announced the acquisition of leading companies in the blood products industry, Pailin Biotechnology, and the pharmaceutical glass industry, Shandong Medicinal Glass, becoming typical cases of mergers and acquisitions in the pharmaceutical industry. (New Society)